Ro 3-0417
Ro 3-0417 is a chemical compound that has been studied for its potential pharmacological effects. It is part of a class of compounds known as benzodiazepines, which are known for their effects on the central nervous system, particularly their ability to modulate the GABA (gamma-aminobutyric acid) neurotransmitter system.
Pharmacology[edit | edit source]
Ro 3-0417 is believed to act as a GABA_A receptor modulator. The GABA_A receptor is a type of receptor in the brain that responds to the neurotransmitter GABA, the primary inhibitory neurotransmitter in the central nervous system. By modulating this receptor, Ro 3-0417 may enhance the inhibitory effects of GABA, leading to sedative, anxiolytic, muscle relaxant, and anticonvulsant effects.
Chemical Structure[edit | edit source]
The chemical structure of Ro 3-0417 is characterized by the presence of a benzodiazepine core, which is a bicyclic structure consisting of a benzene ring fused to a diazepine ring. This structure is common among benzodiazepines and is crucial for their binding to the GABA_A receptor.
Research and Development[edit | edit source]
Ro 3-0417 has been the subject of various preclinical studies to evaluate its pharmacological profile. These studies aim to understand its efficacy, potency, and safety profile compared to other benzodiazepines. However, as of the latest updates, Ro 3-0417 has not been approved for clinical use and remains a compound of interest primarily in research settings.
Potential Applications[edit | edit source]
Due to its mechanism of action, Ro 3-0417 may have potential applications in the treatment of conditions such as anxiety disorders, insomnia, muscle spasms, and epilepsy. However, further research is needed to fully understand its therapeutic potential and safety.
Safety and Side Effects[edit | edit source]
As with other benzodiazepines, potential side effects of Ro 3-0417 may include drowsiness, dizziness, confusion, and impaired coordination. Long-term use of benzodiazepines can lead to tolerance, dependence, and withdrawal symptoms upon discontinuation.
Also see[edit | edit source]
Benzodiazipines[edit source]
- Alprazolam
- Chlordiazepoxide
- Diazepam (Oral)
- Estazolam
- Flurazepam
- Lorazepam
- Midazolam
- Oxazepam
- Quazepam
- Temazepam
- Triazolam
Anticonvulsants Drugs[edit source]
Drug class for Ro 3-0417[edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD